Trials / Unknown
UnknownNCT05404074
Pharmacokinetics of Cobitolimod Enemas in Participants With Active Ulcerative Colitis
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (estimated)
- Sponsor
- InDex Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the PK, safety and tolerability of cobitolimod ememas (500mg/50mL) given to participants with active left-sided UC.
Detailed description
This is a single centre phase 1b study in participants with moderate to severe active UC designed to provide important supplementary data of the PK profile of cobitolimod.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cobitolimod 500mg | Rectal administration |
Timeline
- Start date
- 2021-11-22
- Primary completion
- 2022-10-15
- Completion
- 2022-10-30
- First posted
- 2022-06-03
- Last updated
- 2022-06-10
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT05404074. Inclusion in this directory is not an endorsement.